143 related articles for article (PubMed ID: 25566684)
1. Maintenance chemotherapy in the management of epithelial ovarian cancer.
Markman M
Cancer Metastasis Rev; 2015 Mar; 34(1):11-7. PubMed ID: 25566684
[TBL] [Abstract][Full Text] [Related]
2. PARP inhibitor maintenance therapy for patients with platinum-sensitive recurrent ovarian cancer: a cost-effectiveness analysis.
Smith HJ; Walters Haygood CL; Arend RC; Leath CA; Straughn JM
Gynecol Oncol; 2015 Oct; 139(1):59-62. PubMed ID: 26303225
[TBL] [Abstract][Full Text] [Related]
3. Olaparib: a review of its use as maintenance therapy in patients with ovarian cancer.
Frampton JE
BioDrugs; 2015 Apr; 29(2):143-50. PubMed ID: 25899311
[TBL] [Abstract][Full Text] [Related]
4. Olaparib combined with chemotherapy for recurrent platinum-sensitive ovarian cancer: a randomised phase 2 trial.
Oza AM; Cibula D; Benzaquen AO; Poole C; Mathijssen RH; Sonke GS; Colombo N; Špaček J; Vuylsteke P; Hirte H; Mahner S; Plante M; Schmalfeldt B; Mackay H; Rowbottom J; Lowe ES; Dougherty B; Barrett JC; Friedlander M
Lancet Oncol; 2015 Jan; 16(1):87-97. PubMed ID: 25481791
[TBL] [Abstract][Full Text] [Related]
5. Olaparib in platinum-sensitive ovarian cancer.
Kaji D; Miura Y; Takano T
N Engl J Med; 2012 Jul; 367(2):179; author reply 179-80. PubMed ID: 22784123
[No Abstract] [Full Text] [Related]
6. Quality of life during olaparib maintenance therapy in platinum-sensitive relapsed serous ovarian cancer.
Ledermann JA; Harter P; Gourley C; Friedlander M; Vergote I; Rustin G; Scott C; Meier W; Shapira-Frommer R; Safra T; Matei D; Fielding A; Bennett B; Parry D; Spencer S; Mann H; Matulonis U
Br J Cancer; 2016 Nov; 115(11):1313-1320. PubMed ID: 27824811
[TBL] [Abstract][Full Text] [Related]
7. Challenges in economic modeling of anticancer therapies: an example of modeling the survival benefit of olaparib maintenance therapy for patients with BRCA-mutated platinum-sensitive relapsed ovarian cancer.
Hettle R; Posnett J; Borrill J
J Med Econ; 2015; 18(7):516-24. PubMed ID: 25735651
[TBL] [Abstract][Full Text] [Related]
8. [Maintenance therapy in patients with advanced epithelial ovarian cancer-impact of anti-angiogenic molecular targeted agents in progress].
Takeuchi S; Sugiyama T
Gan To Kagaku Ryoho; 2014 Aug; 41(8):937-43. PubMed ID: 25132025
[TBL] [Abstract][Full Text] [Related]
9. Anti-angiogenic therapy versus dose-dense paclitaxel therapy for frontline treatment of epithelial ovarian cancer: review of phase III randomized clinical trials.
Slaughter KN; Moore KN; Mannel RS
Curr Oncol Rep; 2014 Nov; 16(11):412. PubMed ID: 25292279
[TBL] [Abstract][Full Text] [Related]
10. Advances in epithelial ovarian cancer therapy.
Kroep JR
Curr Pharm Des; 2012; 18(25):3735-40. PubMed ID: 22591426
[TBL] [Abstract][Full Text] [Related]
11. Maintenance therapy in epithelial ovarian cancer: from chemotherapy to targeted agents.
Falci C; Dieci MV; Guarneri V; Soldà C; Bria E; Tortora G; Conte P
Expert Rev Anticancer Ther; 2014 Sep; 14(9):1041-50. PubMed ID: 24953376
[TBL] [Abstract][Full Text] [Related]
12. Olaparib in patients with recurrent high-grade serous or poorly differentiated ovarian carcinoma or triple-negative breast cancer: a phase 2, multicentre, open-label, non-randomised study.
Gelmon KA; Tischkowitz M; Mackay H; Swenerton K; Robidoux A; Tonkin K; Hirte H; Huntsman D; Clemons M; Gilks B; Yerushalmi R; Macpherson E; Carmichael J; Oza A
Lancet Oncol; 2011 Sep; 12(9):852-61. PubMed ID: 21862407
[TBL] [Abstract][Full Text] [Related]
13. Chemotherapy for ovarian cancer: an evidence-based approach.
Geisler JP; Manahan KJ; Wiemann MC
Minerva Ginecol; 2004 Dec; 56(6):539-45. PubMed ID: 15729206
[TBL] [Abstract][Full Text] [Related]
14. NICE guidance on olaparib for maintenance treatment of patients with relapsed, platinum-sensitive, BRCA mutation-positive ovarian cancer.
Tucker H; Charles Z; Robertson J; Adam J
Lancet Oncol; 2016 Mar; 17(3):277-8. PubMed ID: 26827244
[No Abstract] [Full Text] [Related]
15. Made-to-measure medicine: BRCA and gynaecological cancer.
Foulkes WD
Lancet Oncol; 2014 Jul; 15(8):783-5. PubMed ID: 24882435
[No Abstract] [Full Text] [Related]
16. Economic impact of olaparib on maintenance treatment of patients with BRCA-mutation positive, platinum-sensitive relapsing high-grade serous epithelial ovarian cancer in Spain.
Delgado-Ortega L; Ginés Rubió J; Garcías de España MDC; Carcedo D; Cordero Puentes L; Moya de Alarcón C
Farm Hosp; 2018 May; 42(3):95-102. PubMed ID: 29730979
[TBL] [Abstract][Full Text] [Related]
17. Emerging therapies: angiogenesis inhibitors for ovarian cancer.
Jackson AL; Eisenhauer EL; Herzog TJ
Expert Opin Emerg Drugs; 2015 Jun; 20(2):331-46. PubMed ID: 26001052
[TBL] [Abstract][Full Text] [Related]
18. Maintenance therapy in ovarian cancer.
Khalique S; Hook JM; Ledermann JA
Curr Opin Oncol; 2014 Sep; 26(5):521-8. PubMed ID: 25033374
[TBL] [Abstract][Full Text] [Related]
19. Management of relapsed/refractory epithelial ovarian cancer: current standards and novel approaches.
Lin H; Changchien CC
Taiwan J Obstet Gynecol; 2007 Dec; 46(4):379-88. PubMed ID: 18182343
[TBL] [Abstract][Full Text] [Related]
20. [Olaparib in ovarian cancer with BRCA mutation].
Pujade-Lauraine É; Combe P
Bull Cancer; 2015 Jun; 102(6 Suppl 1):S82-4. PubMed ID: 26118881
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
